# A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

> clinical trial · VERIFIED · 2026-07-16

Status: RECRUITING · Sponsor: AstraZeneca · Condition: Pan-tumor(NSCLC, GYN Cancers, BTC and UC)

- Company: AstraZeneca
- Sector: diagnostics
- Primary source: https://clinicaltrials.gov/study/NCT07404202

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.